NDM
Neuroimmunology and Disease Models
Thursday, June 2, 2022: 5:00 PM-7:00 PM
Prince George's Exhibit Hall (Gaylord National Resort & Convention Center)
Effects of Inebilizumab on Attack Severity and Biomarkers of Disease Activity in Neuromyelitis Optica Spectrum Disorder (NMOSD): N-Momentum Study
Jeffrey L Bennett, MD, PhD, University of Colorado, School of Medicine, Anschutz Medical Campus;
Michael A Smith, PhD, Horizon Therapeutics;
Kristina R Patterson, MD, PhD, Horizon Therapeutics plc;
Brian G Weinshenker, MD, Mayo Clinic
Impact of Low Affinity IgG Fc Region Receptor III-a Gene Polymorphisms on Neuromyelitis Optica Spectrum Disorder Treatment Outcomes: N-Momentum Study
Orhan Aktas, MD, Heinrich-Heine University;
Jeffrey L Bennett, MD, PhD, University of Colorado, School of Medicine, Anschutz Medical Campus;
Brian G Weinshenker, MD, Mayo Clinic;
Friedemann Paul, MD, Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin;
Ho Jin Kim, MD, Research Institute and Hospital of National Cancer Center;
Hans-Peter Hartung, MD, Heinrich-Heine University, University of Sydney;
William B Rees, PhD, Horizon Therapeutics plc;
Dewei She, PhD, Horizon Therapeutics plc;
Eliezer Katz, MD, FACS, Horizon Therapeutics plc;
Bruce A.C. Cree, MD, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco
Prevalence of Iatrogenic Central Nervous System Inflammation at a Tertiary Neuroimmunology Clinic
Hannah Kelly, BS, Case Western Reserve University School of Medicine;
Jessica Johnson, BS, Cleveland Clinic Lerner College of Medicine;
Collin Jakubecz, PharmD, University Hospitals Home Care Services;
Alessandro Serra, MD, PhD, University Hospitals Cleveland Medical Center;
Hesham Abboud, MD, PhD, University Hospitals Cleveland Medical Center, Case Western Reserve University
